94 related articles for article (PubMed ID: 35387496)
1. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.
Khankhel ZS; Goring S; Bobiak S; Lamy FX; Nayak D; Garside J; Reese ES; Schoenherr N
Future Oncol; 2022 Jun; 18(18):2321-2338. PubMed ID: 35387496
[TBL] [Abstract][Full Text] [Related]
2. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.
Amonkar MM; Abderhalden LA; Fox GE; Frederickson AM; Grira T; Gozman A; Malhotra U; Malbecq W; Akers KG
Future Oncol; 2024 Apr; 20(13):863-876. PubMed ID: 38353044
[No Abstract] [Full Text] [Related]
4. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
Ying J; Chen J
Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
Cosgrove DP; Reese ES; Fulcher NM; Bobiak SS; Lamy FX; Allignol A; Boyd M; Mahmoudpour SH
Cancer Med; 2023 Feb; 12(4):4195-4205. PubMed ID: 36263922
[TBL] [Abstract][Full Text] [Related]
7. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Valle JW; Vogel A; Denlinger CS; He AR; Bai LY; Orlova R; Van Cutsem E; Adeva J; Chen LT; Obermannova R; Ettrich TJ; Chen JS; Wasan H; Girvan AC; Zhang W; Liu J; Tang C; Ebert PJ; Aggarwal A; McNeely SC; Moser BA; Oliveira JM; Carlesi R; Walgren RA; Oh DY
Lancet Oncol; 2021 Oct; 22(10):1468-1482. PubMed ID: 34592180
[TBL] [Abstract][Full Text] [Related]
8. Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
Mathers B; Abadi S; Davies JM; McIntyre C; Ho C
J Oncol Pharm Pract; 2023 Sep; 29(6):1381-1386. PubMed ID: 36320173
[TBL] [Abstract][Full Text] [Related]
9. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
[TBL] [Abstract][Full Text] [Related]
10. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
11. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada.
Beaulieu C; Lui A; Yusuf D; Abdelaziz Z; Randolph B; Batuyong E; Ghosh S; Bathe OF; Tam V; Spratlin JL
Curr Oncol; 2021 Jan; 28(1):417-427. PubMed ID: 33450805
[No Abstract] [Full Text] [Related]
12. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Kim BJ; Yoo C; Kim KP; Hyung J; Park SJ; Ryoo BY; Chang HM
Br J Cancer; 2017 Feb; 116(5):561-567. PubMed ID: 28081540
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial.
Jin S; Zhao R; Zhou C; Zhong Q; Shi J; Su C; Li Q; Su X; Chi H; Lu X; Jiang G; Chen R; Han J; Jiang M; Qiao S; Liu J; Song M; Song L; Du Y; Chang Z; Wang M; Dong M; Zhong Y; Yu P; Zhang X; Zong H
Int J Cancer; 2023 Apr; 152(8):1648-1658. PubMed ID: 36444498
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY.
Rizzo A; Cusmai A; Giovannelli F; Acquafredda S; Rinaldi L; Misino A; Palmiotti G
Expert Rev Gastroenterol Hepatol; 2022 Mar; 16(3):273-278. PubMed ID: 35220866
[TBL] [Abstract][Full Text] [Related]
15. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.
Rizzo A; Salati M; Frega G; Merz V; Caputo F; Di Federico A; Palloni A; Carloni R; Ricci AD; Gadaleta-Caldarola G; Messina C; Spallanzani A; Gelsomino F; Benatti S; Luppi G; Melisi D; Dominici M; Brandi G
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363500
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Ulusakarya A; Karaboué A; Ciacio O; Pittau G; Haydar M; Biondani P; Gumus Y; Chebib A; Almohamad W; Innominato PF
BMC Cancer; 2020 Jun; 20(1):515. PubMed ID: 32493242
[TBL] [Abstract][Full Text] [Related]
17. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.
Mahmood RD; Graham K; Gleeson J; Hubner RA; Valle JW; McNamara MG
Immunotherapy; 2023 May; 15(7):517-530. PubMed ID: 37009698
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
Arkenau HT; Martin-Liberal J; Calvo E; Penel N; Krebs MG; Herbst RS; Walgren RA; Widau RC; Mi G; Jin J; Ferry D; Chau I
Oncologist; 2018 Dec; 23(12):1407-e136. PubMed ID: 29853658
[TBL] [Abstract][Full Text] [Related]
19. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.
Chen X; Qin S; Gu S; Ren Z; Chen Z; Xiong J; Liu Y; Meng Z; Zhang X; Wang L; Zhang X; Zou J
Int J Cancer; 2021 Dec; 149(11):1944-1954. PubMed ID: 34309846
[TBL] [Abstract][Full Text] [Related]
20. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp).
Javle MM; Oh DY; Ikeda M; Yong WP; Hsu K; Lindmark B; McIntyre N; Firth C
ESMO Open; 2022 Feb; 7(1):100314. PubMed ID: 34922298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
